A comparative study on surgical outcomes of trabeculectomy with and without anti-metabolites in juvenile open-angle glaucoma

Purpose: To compare the surgical outcomes of trabeculectomy with and without anti?metabolites in patients with juvenile open?angle glaucoma (JOAG). Methods: This retrospective comparative case series included 98 eyes of 66 patients with JOAG who underwent either trabeculectomy without anti?metabolites (group A, n = 53 eyes) or with anti?metabolites (group B, n = 45 eyes) with a minimum of 2 years follow?up. The main outcome measures were intra?ocular pressure (IOP), number of glaucoma medications, visual acuity, additional surgical interventions, surgical complications, and risk factors for failure. Surgical failure was defined as IOP >18 mmHg or failure to reduce IOP by <30% from the baseline value or IOP ?5 mmHg or re?operation for refractory glaucoma or a complication or loss of light perception vision. Results: The mean post?operative IOP reduced significantly from baseline at all post?operative visits until 6 months and thereafter. The cumulative probability of failure at 2 years was 28.7% in group A [95% confidence interval (CI) = 17.6–44.8%] and 29.1% in group B (95% CI = 17.1–46.7%) (P = 0.78). Surgical complications occurred in 18 eyes (34%) in group A and 19 eyes (42%) in group B. Re?operations for glaucoma or complications were performed in two eyes (3.8%) in group A and two eyes (4.4%) in group B. Cox?hazard regression model revealed male gender (HR = 0.29; P = 0.008), baseline high IOP (HR = 0.95; P = 0.002), and an increased number of pre?operative glaucoma medications (HR = 2.08; P = 0.010) as significant factors associated with failure. Conclusion: Our study results on trabeculectomy in JOAG revealed a success of 71% in both groups at 2 years follow?up. There was no significant difference in success or failure rates between the two groups. The risk factors for poor surgical outcome in JOAG were male gender, baseline high IOP, and an increased number of glaucoma medications

Determining the Presence of 5-Fluorouracil in Hamster Saliva by HPLC / Determinação, por CLAE, da Presença do 5-Fluorouracil em Saliva de Hamsters

Abstract Introduction: Various methods of analysis for the assay of chemotherapeutic agent 5-Fluorouracil (5-FU) in human and animal biological fluids have previously been reported. However, there is no standardization for detecting 5-FU in the hamsters' saliva that received the chemotherapeutic agent. Objective: Considering that the administration of 5-FU in some way changes the morphology and function of the salivary glands, and that the presence of the chemotherapeutic agents in the oral mucosa may lead to some oral complications, the aim of this study was to determine the presence of 5-FU in the hamsters' saliva that received the chemotherapeutic agent, by means of the High Performance Liquid Chromatography technique (HPCL) since this animal model is used in studies of 5-FU induced oral mucositis and glandular hypofunction. Methods: Twelve animals were divided into 4 groups: CP and CPI, in which the animals received pilocarpine (CP) or pilocarpine + isoproterenol (CPI) and the chemotherapy vehicle intraperitoneally; and Groups QP and QPI, in which the animals received the same secretagogues listed above, and the chemotherapeutic agent 5-FU, respectively. After the secretagogue administration, saliva was collected from all the animals for a period of 60 mins. Subsequently, the saliva was frozen at -80 ˚C for later determination of the chemotherapeutic agent by HPLC. After the the chromatograms analysis, and based on the results obtained, it was possible to identify the presence of 5-FU in the saliva samples from hamsters that received the chemotherapeutic agent intraperitonally, by the HPLC technique. (AU)

Resumo Vários métodos de análise para o ensaio do quimioterápico 5-Fluorouracil (5-FU) em fluidos biológicos de humanos e animais, foram previamente relatados. No entanto, não há uma padronização para detecção de 5-FU na saliva de hamsters que receberam o quimioterápico. Considerando que a administração do 5-FU altera de alguma maneira a morfologia e função das glândulas salivares, e que a presença do quimioterápico na mucosa oral pode levar a algumas complicações orais, este trabalho teve como objetivo de determinar a presença de 5-FU na saliva de hamsters que receberam o quimioterápico pela técnica de Cromatografia Líquida de Alta Eficiência (CLAE), uma vez que este modelo animal é usado nos estudos com mucosite oral e hipofunção glandular, induzidas por 5-FU. Doze animais foram divididos em 4 grupos: CP e CPI, onde os animais receberam intraperitonealmente pilocarpina (CP) ou pilocarpina + isoproterenol (CPI) e o veículo do quimioterápico, e os grupos QP e QPI, onde os animais receberam, respectivamente, os mesmos secretagogos listados acima e o quimioterápico 5-FU. Após a administração do secretagogo, foi coletada a saliva de todos os animais, por um período de 60 min. Em seguida, a saliva foi congelada a -80 ˚C para posterior determinação do quimioterápico por CLAE. Após análise dos cromatogramas, e com base nos resultados obtidos, foi possível identificar a presença do 5-FU nas amostras de saliva de hamsters que receberam o quimioterápico via intraperitoneal pela técnica da CLAE. (AU)

Marine drugs for cancer: surfacing biotechnological innovations from the oceans

This review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources.

Research progress of antineoplastic effect of magnesium and zinc alloy / 国际外科学杂志

With its excellent biocompatibility,good biomechanics and biodegradability,magnesium zinc alloy has been widely used in biomaterials,and its antineoplastic effect has attracted more and more attention recently.Osteosarcoma is the most common primary malignant bone tumor.With the improvement of the diagnosis and treatment,the rate of 5-year survival has been greatly improved,which is nearly 60％ ～ 70％.However,local recurrence and metastasis after operation are still main risk factors on the survival quality and clinical function of patients.This paper reviews previous researches concerned the antineoplastic effect about magnesium,zinc and its alloys,and summarized the anti-tumor mechanism of magnesium,zinc and its alloys,and its research value in the field of osteosarcoma.

Research progress of anti-tumor mechanism of effective components of angelica dahurica / 国际中医中药杂志

Angelica dahurica is diaphoretic, commonly used in the treatment of cold, wet, and itchy rubella nasosinusitis. Studies have shown that the effective components of Angelica dahurica can be used in the treatment of malignant tumors. This paper summarizes the related literature home and abroad recently, and regards the effective components of Angelica dahurica as a major role in treatment of tumor by inhibiting tumor cell proliferation, promoting apoptosis, inhibiting tumor metastasis, inhibiting platelet aggregation, enhancing immunity, and anti-tumor drug resistance. Meanwhile, the paper finds the shortcomings of the present researches, and hopes to provide reference for the future experiment and clinical research.

Clinical study of raltitrexed plus oxaliplatin compared with S1 in treating the patients with advanced primary liver cancer / 国际肿瘤学杂志

Objective To evaluate the therapeutic efficacy and adverse reactions of raltitrexed plus oxaliplatin (RALOX project) and S1 in patients with advanced primary liver cancer.Methods Seventy-one patients with advanced primary liver cancer admitted to 6 cancer centers from July 2013 to July 2015 were divided into 2 groups according to the wishes of the patients and their families:RALOX group (34 patients) and S1 group (37 patients).The therapeutic efficacy such as objective remission rate (ORR),disease control rate (DCR),median overall survival (mOS),median progression free survival (mPFS),one year survival rate (SR),and adverse reactions in these patients were evaluated.Results Thirty-one patients could be evaluated in RALOX group,and 6 patients obtained partial response (PR),10 stable disease (SD) and 15 progressive disease (PD).Thirty-three patients could be evaluated in S1 group,and 3 patients obtained PR,8 patients SD and 22 PD.The ORR,DCR,and one year SR were 19.4％ vs.9.1％,51.6％ vs.33.3％,and 22.6％ vs.12.1％ respectively,and there were no statistically significant differences in the two groups (x2 =1.393,P =0.238;x2 =2.190,P =0.139;x2 =1.229,P =0.268).The mOS and mPFS were 7.2 months vs.6.1 months and 3.4 months vs.2.8 months,and there were statistically significant differences in the two groups (x2 =6.433,P =0.011;x2 =4.078,P =0.043).There was more serious peripheral nerve toxicity (29.0％ vs.3.0％,x2 =6.344,P =0.012) and lighter hand-foot syndrome (9.7％ vs.30.3％,x2 =4.201,P =0.040) in RALOX group than S1 group.But the incidences of other adverse effects were similar in the two groups.Condnsion RALOX project is safe and effective to the patients with advanced primary liver cancer.Compare with S1 project,RALOX project has better curative effects and the majority of adverse reactions are tolerable.The patients have good condition control and survival benefit.

Revisión con aguja asociada a mitomicina C en ampollas de filtración encapsuladas / Mitomycin C-associated needle revision in encapsulated filtering blebs

Objetivo: determinar la efectividad a mediano plazo de la revisión con aguja asociada a mitomicina C en la ampolla de filtración encapsulada postrabeculectomía. Métodos: estudio observacional descriptivo, prospectivo de serie de casos (30 ojos, 30 pacientes), con antecedentes de quiste de Tenon a corto plazo postrabeculectomía (1 mes-1 año). Se realizó revisión con aguja asociada a inyección subconjuntival MMC 0,01 % hasta completar 3 dosis en días alternos. Se evaluaron la presión intraocular y el uso de colirios hipotensores preoperatorio y posoperatorio a la semana, 1 mes, 3 meses, 1 año y 2 años. Se definió éxito si la presión intraocular era menor de 21 mmHg sin colirio hipotensor (éxito total) y con colirios hipotensores (éxito parcial). Se registraron las complicaciones quirúrgicas. Resultados: hubo descenso significativo de la presión intraocular media preoperatoria de 27,06 ± 5,2 mmHg a 13,10 ± 3,65 mmHg, 14,83 ± 3,68 mmHg y 16,70 ± 3,38 mmHg a la semana, 1 y 3 meses posoperatorios respectivamente, y se mantuvo estable hasta 2 años (16,70 ± 2,18 mmHg); p< 0,001 para cada comparación preoperatorio vs. posoperatorio), lo que representó una reducción de la presión intraocular del 51,8 por ciento a la semana; 44,4 por ciento al mes y 37 por ciento hasta los 2 años. La media del número de colirios hipotensores se redujo significativamente de 2,0 ± 0,0 (preoperatorio) a 0,4 ± 0,0 (2 años posoperatorios), p< 0,001. El éxito fue total en el 70 por ciento de los casos y parcial en el 30 por ciento, tras 2 años posoperatorios. Las complicaciones fueron: hemorragia subconjuntival (100 por ciento de casos), atalamia (40 por ciento) y Seidel positivo (26,7 por ciento). Conclusiones: la revisión con aguja asociada a mitomicina C subconjuntival como tratamiento de la ampolla encapsulada, logra reducción del 37 por ciento de la presión intraocular durante los dos primeros años posoperatorios con un mínimo de complicaciones(AU)

Objective: to determine the medium-term effectiveness of subconjuntival mitomicyn-C associated to needle revision on encapsulated filtering bleb after trabeculectomy. Methods: prospective, descriptive and observational case series study (30 eyes, 30 patients) with a history of Tenon cyst after short term trabeculectomy (1month-1year). These patients underwent needle revision associated to subconjuntival 0,01 percent mitomycin injection to completing three doses in every other day. The intraocular pressure and the use of hypotensive drops preoperatively and postoperatively were evaluated seven days, one month, three months, one year and two years after the procedure. The success of intervention was defined as total when the intraocular pressure was less than 21mmHg without hypotensive drops and partial with hypotensive drops. Surgical complications were recorded. Results: the mean preoperative intraocular pressure decreased significantly from 27,06 ± 5,2 mmHg to 13,10 ± 3,3 mmHg, 14,83 ± 3,68 mmHg and 16,70 ± 3,38 mmHg one week, one month and three months after surgery and remained stable (16,70 ± 2,18 mmHg) for 2 years, p< 0,001 for each preoperative and postoperative comparison; this represented an intraocular pressure reduction of 51,8 percent; 44,4 percent and 37 percent after one week, one month, and up to 2 years, respectively. The mean number of hypotensive drops lowered significantly from 2,0 ± 0,0 (preoperative) to 0,4 ± 0,0 (two years after surgery), being p< 0,001. Total success was attained in 70 percent of cases and partial in 30 percent after 2 years. Surgical complications were subconjuntival haemorrhage (in all patients), atalamy (40 percent) and positive Seidel index (26,7 percent). Conclusion: subconjuntival mitomicyn-C injection-associated needle revision for encapsulated bleb reduces intraocular pressure by 37 percent during the first 2 years after the procedure with minimal complications(AU)

Research advances in prevention and treatment of primary liver cancer with metabolic agents / 临床肝胆病杂志

Recently, more and more studies have shown that the development and progression of primary liver cancer (hereinafter referred to as liver cancer) is closely associated with the metabolism in human body, and metabolic disturbance in human body increases the incidence and mortality of liver cancer. The prevention and treatment of liver cancer with drugs improving metabolism is a hot research topic nowadays. This article introduces three metabolic agents, S-Adenosylmethionine, metformin, and statins, which can be used for the prevention and treatment of liver cancer, as well as their association with the pathogenesis of liver cancer and possible mechanisms of action. The article points out that further studies are needed to investigate the association between metabolism and the pathogenesis of liver cancer, in order to find more metabolic agents for the prevention and treatment of liver cancer in future.

Insights into the role of NAMPT and its inhibitors in the metabolism of tumor cells / 肿瘤

Different from normal cells, tumor cells display a metabolic profile by facilitate glycolysis pathway to provide adenosine triphosphate (ATP) quickly for cell growth and survival. Therefore, the demand of nicotinamide adenine dinucleotide (NAD), an important coenzyme in glycolysis pathway, increases obviously in tumor cells. It has been reported that tumor cells synthetize NAD through the primary salvage pathway, in which nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme. As such, NAMPT regulates the cellular metabolism directly through controlling NAD synthesis and indirectly via affecting the activity of NAD-dependent enzymes. Meanwhile, NAMPT can ensure the viability of tumor cells by up-regulating the level of nicotinamide adenine dinucleotide phosphate (NADPH). Recently, NAMPT has been proposed as a new potential target for cancer treatment, and a number of studies have implicated that the NAMPT inhibitor has obvious anti-cancer effects. This review summarizes the alternation of metabolism in tumor cells, highlights the crucial role of NAMPT in cellular metabolism, and discusses the anticancer effect and the potential clinical application of NAMPT inhibitors in cancer treatment.

Síndrome hemolítico-urémico asociado al uso de gemcitabina: Caso clínico / Hemolytic-uremic syndrome associated with gemcitabine use: Report of one case

Gemcitabine is a widely used drug in the treatment of advanced pancreatic cancer and other malignancies. It is generally well tolerated and exceptionally its use has been associated with hemolytic-uremic syndrome, causing acute kidney injury, hipertension, chronic renal failure requiring dialysis, and death. We report a 60-year-old man with pancreatic carcinoma and regional lymph node invasion, whom after four months of therapy with gemcitabine and after dose number 11, suddenly developed an acute nephritic syndrome with moderate renal impairment, associated with severe anemia (hemoglobin 6.0 g/dL) and thrombocytopenia (20,000 mm³). Renal biopsy showed the classic findings of thrombotic micro angiopathy Gemcitabine was discontinued and renal function and hematological parameters gradually improved.

Safe Excision of a Large Overhanging Cystic Bleb Following Autologous Blood Injection and Compression Suture

Here, we report a large, overhanging cystic bleb that compromised vision and induced a foreign body sensation in a patient who underwent a trabeculectomy surgery with anti-metabolite therapy 4 years prior. Ultrasound biomicroscopy revealed multiple loculations with thin septa inside the bleb and a high risk of damage to the bleb was anticipated with a straight forward surgical excision. We injected autologous blood and placed a compression suture 6 weeks prior to surgical excision of the overhanging portion of the bleb. The operation was successful in preserving excellent bleb function, restoring visual acuity, and alleviating symptoms in our patient with up to 9 months of follow-up.

Safe Excision of a Large Overhanging Cystic Bleb Following Autologous Blood Injection and Compression Suture

Here, we report a large, overhanging cystic bleb that compromised vision and induced a foreign body sensation in a patient who underwent a trabeculectomy surgery with anti-metabolite therapy 4 years prior. Ultrasound biomicroscopy revealed multiple loculations with thin septa inside the bleb and a high risk of damage to the bleb was anticipated with a straight forward surgical excision. We injected autologous blood and placed a compression suture 6 weeks prior to surgical excision of the overhanging portion of the bleb. The operation was successful in preserving excellent bleb function, restoring visual acuity, and alleviating symptoms in our patient with up to 9 months of follow-up.

Escape tardío de la bula de filtración a propósito de un caso / Late onset of leaking filtering bleb in a case

Paciente masculino de 48 años, de color de la piel mestizo, al que se le realizó trabeculectomía con antimetabolito en su ojo derecho con daño glaucomatoso avanzado y atrofia óptica glaucomatosa en su ojo izquierdo. Tres años después acude a consulta de seguimiento con escape tardío de la ampolla de filtración, perforación escleral y ligera hipotonía ocular. Surge la disyuntiva entre realizar recubrimiento de la ampolla con trasplante conjuntival autólogo, con el riesgo de elevación posterior de la presión intraocular por encima de su valor meta, y no practicar tratamiento quirúrgico con elevada posibilidad de endoftalmitis. Se realizó el proceder y en el seguimiento se constató un injerto conjuntival bien adaptado y vascularizado, con presión intraocular inferior a 15 mmHg en cada consulta y no progresión del daño glaucomatoso

The case of a 48 years-old male patient was presented. He underwent trabeculectomy with antimetabolites to treat advanced glaucomatous damage in his right eye and optical glaucomatous atrophy in his left eye. After three years, he went to the follow-up medical service with late-onset of leaking filtering bleb, sclera perforation and slight ocular hypotony. The dilemma of covering the bleb with conjunctival autologous graft, with the risk of raised intraocular pressure over the target value o non-performance of the surgical treatment with high possibility of endophthalmitis was present. It was decided to apply the surgical procedure. The follow-up showed a well-adapted and vascularized conjunctival graft and intraocular pressure lower than 15 mm Hg in each medical appointment, without advance in glaucomatous damage

Comparative Study of Encapsulated Blebs Following Ahmed Glaucoma Valve Implantation and Trabeculectomy with Mitomycin-C

PURPOSE: To compare the histopathologic and morphologic findings of encapsulated blebs following Ahmed glaucoma valve implantation and primary standard trabeculectomy with mitomycin-C. METHODS: We reviewed the records of patients with otherwise uncontrollable glaucoma who had undergone Ahmed glaucoma valve implantation or trabeculectomy with mitomycin-C. Five eyes that underwent Ahmed valve implantation and three eyes that underwent trabeculectomy needed surgical revision of the initial surgery due to encapsulated bleb development with total loss of function. The surgically removed encapsulated blebs were analyzed macroscopically and microscopically. RESULTS: Removal of the encapsulated bleb was performed at a mean follow-up time of 26.6 +/- 19.4 weeks in the Ahmed valve implantation group and 12.0 +/- 11.4 weeks in the trabeculectomy group. The fibrotic wall of the encapsulated blebs had an overall thickness of 2.48 +/- 0.42 mm in the Ahmed valve implantation group and 1.62 +/- 0.37 mm in the trabeculectomy group. Macroscopically, the coconut flesh-like smooth surface was split into two layers, and the wall of the capsule was thicker in the Ahmed valve implantation group than in the trabeculectomy group. Histopathologically, the fibrotic capsule was composed of an inner fibrodegenerative layer and an outer fibrovascular layer, and there were no histopathological differences between the two groups. CONCLUSIONS: The fibrotic capsule wall was thicker in the Ahmed valve group, but there were no differences in histological findings between the two groups.

Sequential versus combined glaucoma and cataract procedures in Siriraj Hospital.

Objective: To compare the efficacy of intraocular pressure (IOP) control after combined cataract and trabeculectomy with sequential cataract surgery after trabeculectomy, both with and without antimetabolites. Methods: The retrospective study recruited 96 eyes of 73 patients who underwent cataract and glaucoma surgery, and were classified into two groups. Group I sequential procedures: 72 eyes of 56 patients who had undergone a previous trabeculectomy (with or without antimetabolites) for at least 6 months before planned phacoemulsification or ECCE. Groups II combined procedures: 24 eyes of 17 patients who underwent combined trabeculectomy(with or without antimetabolites) with phacoemulsification or ECCE between January 1998 and May 2003. The effects on IOP, best corrected visual acuity, and number of glaucoma medications taken were compared. Results: Mean postoperative IOP without oral medications was 14.17 mmHg in group I and 17.15 mmHg in group II (p=0.05) at 12 month follow up. The mean IOP remained significantly lower in group I (13.67) than in group II (16.36) (p=0.023) at the last follow up. There was a significant difference in surgical success between the groups (p=0.005). The reduction in the mean number of glaucoma medications was significantly higher in group I (p=0.04). In group I the mean IOP before and after cataract surgery were similar (p=0.787) but the numbers of glaucoma medications used were significantly increased (p=0.000) after cataract surgery. Conclusion: Sequential glaucoma and cataract procedure was associated with better IOP control than combined procedure. Cataract surgery in eyes with functioning bleb might have the adverse effect on IOP control.

The Effect of Revision Endoscopic Dacryorhinostomy (EDCR)

PURPOSE: The purpose of this study was to evaluate the effects of revision endoscopic endonasal dacryocystorhinostomy (EDCR) and the causes of postoperative failure after primary endoscopic DCR in patients with nasolacrimal duct obstruction. METHODS: This prospective study enrolled 32 patients (32 eyes) who had undergone revision of endoscopic DCR with the diagnosis of obstruction of nasolacrimal system after primary EDCR between October 1997 and February 2003. RESULTS: The most common cause of revision operation after primary EDCR was granuloma, followed by membranous obstruction and common canalicular obstruction. The success rate of the cases with granuloma was 69.2%, and that with membranous obstruction was 100%. CONCLUSIONS: Revision EDCR success rate can be improved by reducing the frequency of granuloma as this was the most common factor for revision EDCR. The effect of antimetabolites in revision EDCR success rate is to be further evaluated.

Effects of Antimetabolites on Proliferation of Rabbit Retinal Pigment Epithelial Cells

Inspite of technical advances, the need for pharmacologic treatment of proliferative vitreoretinopathy was increased. In order to evaluate the antiproliferative effect of various antimetabolites to the rabbit retinal pigment epithelial cell, we treated cultured rabbit retinal pigment epithelial cell with different concentration of drugs to perform dose inhibition studies. We found that the antimetabolites inhibited the proliferation of rabbit retinal pigment epithelial cell in a dose dependent and a time dependent manner. The drug concentration required for 50% inhibition of cell growth (ID50) were found to be as follows (BCNU; 6.51 mg/L, 5-FU ; 8.94 mg/L, Daunorubicin; 0.03mg/L, Mitomycin-C; 0.26mg/L).